Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance.
about
Is AMH a regulator of follicular atresia?The impact of smoking on antimüllerian hormone levels in women aged 38 to 50 yearsAge related endocrine patterns observed in polycystic ovary syndrome patients vs. ovulatory controls: descriptive data from a university based infertility center.Is AMH Level, Independent of Age, a Predictor of Live Birth in IVF?Maternal antimullerian hormone levels do not predict fetal aneuploidy.Anti-Müllerian hormone levels in the follicular fluid of the preovulatory follicle: a predictor for oocyte fertilization and quality of embryo.Variations in serum müllerian inhibiting substance between white, black, and Hispanic women.Changes in plasma müllerian-inhibiting substance and brain-derived neurotrophic factor after chemotherapy in premenopausal womenAnti Müllerian Hormone (AMH) level and expression in mural and cumulus cells in relation to age.Impact of CD4+ lymphocytes and HIV infection on Anti-Müllerian Hormone levels in a large cohort of HIV-infected and HIV-uninfected womenReduced neurotrophin receptor tropomyosin-related kinase A expression in human granulosa cells: a novel marker of diminishing ovarian reserve.Aromatase (CYP19) gene variants influence ovarian response to standard gonadotrophin stimulation.The role of vitamin D in reproductive health--a Trojan Horse or the Golden Fleece?Differential granulosa cell gene expression in young women with diminished ovarian reserve.Maximum basal FSH predicts reproductive outcome better than cycle-specific basal FSH levels: waiting for a "better" month conveys limited retrieval benefitsCirculating vitamin D correlates with serum antimüllerian hormone levels in late-reproductive-aged women: Women's Interagency HIV Study.Possible involvement of single nucleotide polymorphisms in anti-Müllerian hormone signaling pathway in the pathogenesis of early OHSS in Han Chinese women.Obesity adversely affects serum anti-müllerian hormone (AMH) levels in Caucasian womenAutologous oocyte cryopreservation in women aged 40 and older using minimal stimulation IVF.Use of anti-mullerian hormone for testing ovarian reserve: a survey of 796 infertility clinics worldwideMaternal antimullerian hormone as a predictor of fetal aneuploidy occurring in an early pregnancy loss.Prediction of Poor Ovarian response by Biochemical and Biophysical Markers: A Logistic Regression Model.The ovarian response to standard gonadotrophin stimulation depends on FSHR, SHBG and CYP19 gene synergismDiagnosis and treatment of diminished ovarian reserve in assisted reproductive technology cycles of women up to age 40 years: the role of insurance mandates.Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve.Is there an ideal stimulation regimen for IVF for poor responders and does it change with age?Prediction and diagnosis of poor ovarian response: the dilemma.Effects of testosterone on the expression levels of AMH, VEGF and HIF-1α in mouse granulosa cellsIntrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle-stimulating hormone (FSH) in normoandrogenic ovulatory women undergoing gonadotropin releasing-hormone analog/recombinant human FSH therapy for in vitro fertiliDetermining an anti-Mullerian hormone cutoff level to predict clinical pregnancy following in vitro fertilization in women with severely diminished ovarian reserve.Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Müllerian hormone versus small antral follicle count (2-6 mm)Anti-Müllerian hormone as a marker of ovarian reserve: an update.Potential mechanisms for racial and ethnic differences in antimüllerian hormone and ovarian reserve.Early prenatal androgenization results in diminished ovarian reserve in adult female rhesus monkeys.Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART).Serum and follicular fluid Anti-Mullerian hormone concentrations at the time of follicle puncture and reproductive outcome.Intensive care treatment of ovarian hyperstimulation syndrome (OHSS).Anti-Müllerian hormone in women with polycystic ovary syndrome.AMH after laparoscopic surgery of the ovaries: a review.Fertility issues in cancer survivorship.
P2860
Q27006736-72FF1885-1B87-4047-8C1E-0C90329D018BQ28395441-6DB47473-2487-45FB-A444-ECBE0ADE8B5DQ31136481-307FC831-F674-4F41-977F-BEC88AB1FAB6Q33604947-BBEC9D07-1D77-4F14-B580-F9A739F6B5F6Q34070204-2EBA5537-867B-4AF0-AD9E-314A79A5CFA2Q34208331-EDB32D35-44DC-438A-B35D-23F19DF4F3D0Q34568747-597BFD61-D592-4594-B54F-1A5279932C55Q34618818-7710F8ED-B715-4903-9B2B-63936B96000CQ34728091-D5F7E8F1-C9CE-4545-8B86-E6E8E3EA6042Q35070210-3C11455B-394E-4093-BF9B-CC56DB6069FCQ35126929-54CD9E78-AF1A-444D-BA4D-8541EAF9BC48Q35722666-2CFA175D-CC89-4987-8777-34B89E5D0641Q35808839-4883C9CC-ACAA-4010-90CB-2C7B4E1C6450Q35931052-B153D727-4485-4076-8538-3A36E2F6332BQ35953736-885D7AA8-654E-49E0-8E0A-0B473CE87FE3Q36074219-A365DF24-3DA1-4CC9-A0DF-8B84F8731EC1Q36095415-1A4C1CC5-7980-4EB3-BB49-A48FE3D58FA7Q36127723-7A19ED37-31F8-43DA-ACE4-FE90D07CF0DAQ36131108-1AA12DDA-A963-4E2F-9D4A-EDC97887DBA8Q36192080-D65919AA-5D59-4BFE-8FB0-E1C2B83F3BCDQ36328655-166C5EDF-D019-40D3-AEE5-C27F17248D80Q36337226-74635AF3-19A3-46FE-81DF-90F36FF4B0B7Q36434655-042F9098-4398-4EC1-AE7B-7525096205E3Q36579307-54EE7642-72E3-419F-8302-2A5C606200FFQ36995774-FF818003-5A6B-483D-9BAC-474E94E8FF9DQ36995791-C99A5EE3-4F90-48F3-9F54-4E260A838C37Q37035196-DB61C547-A31D-48C2-A6F0-2335BAECD220Q37108532-D1ABDA4E-04AB-4F2B-B91F-9F3A6DCC0F70Q37245167-228D65E5-7258-47F5-9E36-A48B9553A0D0Q37300099-713FA63E-9156-47F2-ACCD-86599854B94EQ37313052-98FD8281-17A3-4D0E-8570-DDF61409A52DQ37346173-F0EDC69B-EA6D-420C-A02E-FFF6564857CEQ37379906-7BC4F56A-7846-42E4-8881-D02EC3251171Q37422114-735C7721-4035-4323-A23C-DBC0F5A19DD5Q37606149-F269958A-BCFC-4337-8ED3-1556D182F48CQ37613324-55F64CBF-F126-4A01-B40B-82D5E99FB1B3Q37852771-8216996C-FD55-46C4-AABB-7B35900C45C2Q37885328-7B1397DA-BCDF-4E78-B58A-167249691172Q38085728-29519184-F287-4FE8-BBB6-65138E69C88EQ38194105-C527EE2D-DC69-4091-A216-A47EE23CD945
P2860
Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Mullerian Inhibiting Substance ...... merging clinical significance.
@ast
Mullerian Inhibiting Substance ...... merging clinical significance.
@en
Mullerian Inhibiting Substance ...... merging clinical significance.
@nl
type
label
Mullerian Inhibiting Substance ...... merging clinical significance.
@ast
Mullerian Inhibiting Substance ...... merging clinical significance.
@en
Mullerian Inhibiting Substance ...... merging clinical significance.
@nl
prefLabel
Mullerian Inhibiting Substance ...... merging clinical significance.
@ast
Mullerian Inhibiting Substance ...... merging clinical significance.
@en
Mullerian Inhibiting Substance ...... merging clinical significance.
@nl
P1476
Mullerian Inhibiting Substance ...... merging clinical significance.
@en
P2093
David B Seifer
David T Maclaughlin
P304
P356
10.1016/J.FERTNSTERT.2007.02.014
P407
P577
2007-06-07T00:00:00Z